Pfizer INC Form 4 insider transactions

Jennifer B. Damico, SVP & Controller at Pfizer Inc, reported the acquisition of 49 phantom stock units through the Pfizer Supplemental Savings Plan on March 28, 2024.

Pfizer's Chairman and CEO, Albert Bourla, reported the acquisition of 19 phantom stock units through the Pfizer Supplemental Savings Plan on March 28, 2024.

Director James C. Smith reports acquisition of phantom stock units representing deferred director's compensation.

Director Shantanu Narayen reported the acquisition of phantom stock units in Pfizer, representing deferred director's compensation.

Director James Quincey reports acquiring phantom stock units representing deferred director's compensation in Pfizer Inc.

Director Joseph Echevarria reported the acquisition of phantom stock units representing deferred director's compensation in a recent SEC filing.

Jennifer B. Damico, SVP & Controller of Pfizer Inc., reported the acquisition of 87 phantom stock units through the Pfizer Supplemental Savings Plan on March 15, 2024.

Pfizer's Chairman and CEO, Albert Bourla, reported the acquisition of 8 phantom stock units through the Pfizer Supplemental Savings Plan on March 15, 2024.

Pfizer's CEO, Albert Bourla, reports an intra-plan transfer involving Pfizer stock units within the company's Supplemental Savings Plan.

Executive Vice President Christoffel Boshoff reports acquisition and disposal of Pfizer shares related to performance share awards.

Mikael Dolsten, President of R&D at Pfizer, reports the withholding of shares to cover tax obligations upon settlement of stock units.

Pfizer's Chief Financial Officer, David M. Denton, acquired stock appreciation rights (SARs) that will be settled in shares of Pfizer common stock, according to a recent SEC filing.

Executive Vice President Lidia Fonseca reports acquisition of stock appreciation rights related to Pfizer common stock.

Executive Vice President Michael McDermott reported the acquisition of stock appreciation rights (SARs) tied to Pfizer common stock.

Executive Vice President Christoffel Boshoff reports the acquisition of stock appreciation rights (SARs) tied to Pfizer common stock.

Mikael Dolsten, President of R&D at Pfizer, acquired stock appreciation rights (SARs) that will be settled in Pfizer common stock.

Executive Vice President Sally Susman reports the acquisition of stock appreciation rights (SARs) tied to Pfizer common stock.

Executive Vice President Aamir Malik acquired stock appreciation rights (SARs) tied to Pfizer common stock, according to a Form 4 filing with the SEC.

Pfizer's CEO, Albert Bourla, was granted stock appreciation rights (SARs) that will be settled in shares of Pfizer common stock.

Executive Vice President Rady A. Johnson reports the acquisition of stock appreciation rights related to Pfizer common stock.

Executive Vice President Payal Sahni reports the acquisition of stock appreciation rights related to Pfizer common stock.

Executive Vice President of Pfizer, Douglas M. Lankler, reports acquisition of stock appreciation rights (SARs) tied to Pfizer common stock.

Jennifer B. Damico, SVP & Controller of Pfizer Inc., reports the acquisition of restricted stock units and stock appreciation rights.

Executive Vice President Alexandre de Germay reports acquisition of Pfizer stock and stock appreciation rights on February 27, 2024.

Executive Vice President Michael McDermott reports the earn-out of stock appreciation rights and withholding of shares for tax obligations and exercise price payments.

Sally Susman, Executive Vice President of Pfizer, reports the earn-out of stock appreciation rights and related transactions on February 23, 2024.

Executive Vice President Payal Sahni reports the earn-out of stock appreciation rights and related transactions, including share withholding for tax obligations and exercise price payments.

Executive Vice President Douglas M. Lankler reports the earn-out and subsequent transactions of stock appreciation rights, including share withholding for tax obligations and exercise price, affecting his beneficial ownership of Pfizer common stock.

Executive Vice President Rady A. Johnson reports the earn-out of stock appreciation rights and related transactions involving Pfizer Inc. common stock.

Mikael Dolsten, President of R&D at Pfizer, reports the withholding of shares to cover tax obligations upon settlement of stock units.